Ricevi le ultime notizie sulle azioni SELLAS Life Sciences Gr con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SLS

Ultime notizie per

SELLAS Life Sciences Gr

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Group Inc

Solaris Resources Inc

Solesence Inc

Solasto Corp

SELECT SANDS CORP ORD by Select Sands Corp.

Select Sands Corp

Solaris Resources Inc Ordinary Shares

News

Press Releases

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

Management

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

Small Cap

Opinion

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Health Care

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Earnings

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

AUTL

CATX

GOVX

INDP

ONCY

OSTX

TSX:ONC

ZAILF

ZLAB

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

C4 Therapeutics

Coherus Oncology

Caribou Biosciences

Citius Oncology

Elicio Therapeutics

Forte Biosciences

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Seres Therapeutics

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Zura Bio Limited - Class A Ordinary shares

Comments

SELLAS Life Sciences Gr Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO